(VIANEWS) – Shares of BeiGene (NASDAQ: BGNE) rose 9.49% to $232.12 at 12:28 EST on Thursday, following the last session’s downward trend. NASDAQ is rising 0.49% to $12,055.31, after three successive sessions in a row of losses. This seems, at the moment, a somewhat bullish trend trading session today.
BeiGene’s last close was $212.00, 24.45% under its 52-week high of $280.62.
About BeiGene
BeiGene, Ltd., a biotechnology company, focuses on discovering, developing, manufacturing, and commercializing various medicines worldwide. Its products include BRUKINSA to treat relapsed/refractory (R/R) mantle cell lymphoma; Tislelizumab to treat R/R classical Hodgkin's lymphoma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplastic syndromes, chronic myelomonocyte leukemia, and acute myeloid leukemia; XGEVA to treat giant cell tumor of bone; BLINCYTO to treat acute lymphoblastic leukemia; KYPROLIS to treat R/R multiple myeloma; SYLVANT to treat idiopathic multicentric castleman disease; QARZIBA to treat neuroblastoma; Pamiparib for the treatment of various solid tumors; and Pobevcy to treat metastatic colorectal cancer, liver cancer, and non-small cell lung cancer (NSCLC). The company's clinical stage drug candidates comprise Zanubrutinib, a BTK inhibitor to treat lymphomas; Tislelizumab, an anti-PD-1 antibody to treat solid and hematological cancers; Lifirafenib and BGB-3245 to treat melanoma, NSCLC, and endometrial cancer; and Sitravatinib, a multi-kinase inhibitor to treat NSCLC, melanoma, and other solid tumors. Its clinical stage drug candidates also include BGB-A333, a PD-L1 inhibitor to treat various solid tumors; Ociperlimab, a TIGIT inhibitor to treat various solid tumors; BGB-11417, a small molecule Bcl-2 inhibitor to treat mature B-cell malignancies; BGB-A445, an OX40 agonist antibody to treat solid tumors; Zanidatamab, a bispecific HER2 inhibitor to treat breast and gastric cancer; BGB-A425, a T-cell immunoglobulin and mucin-domain containing-3 inhibitor to treat various solid tumors; and BGB-15025, a small molecule inhibitor of HPK1. The company has strategic collaborations with Shoreline Biosciences, Inc., Amgen Inc., Novartis AG, and Bristol Myers Squibb company. BeiGene, Ltd. was incorporated in 2010 and is headquartered in Cambridge, Massachusetts.
Earnings Per Share
As for profitability, BeiGene has a trailing twelve months EPS of $-19.06.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -52.54%.
Volatility
BeiGene’s last week, last month’s, and last quarter’s current intraday variation average was a negative 0.34%, a negative 0.48%, and a positive 1.80%.
BeiGene’s highest amplitude of average volatility was 1.14% (last week), 2.22% (last month), and 1.80% (last quarter).
Volume
Today’s last reported volume for BeiGene is 179533 which is 23.01% below its average volume of 233206.
More news about BeiGene (BGNE).
